Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Next Previous
Trial Profile

An Open-Label, First in Human, Phase 1/2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dencatistat (Primary)
  • Indications B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Step Pharma

Most Recent Events

  • 15 Oct 2025 According to a Step Pharma media release, the company announced the completion of a 38 million euro Series C financing round. These funds will enable company complete all ongoing phase 1 studies and further derisk dencatistat as the company enter phase 2.
  • 06 Jun 2023 Results (n=3; from first cohort) reporting safety data presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 10 May 2023 According to a Step Pharma media release, data from this trial will be presented at the 2023 ASCO Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top